Prazosin treatment of trauma nightmares and sleep disturbance in soldiers deployed in Iraq.

Madigan Army Medical Center and VA Northwest Network Mental Illness, VA Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, WA 98108, USA.
Journal of Traumatic Stress (Impact Factor: 2.72). 10/2010; 23(5):645-8. DOI: 10.1002/jts.20570
Source: PubMed

ABSTRACT Trauma nightmares and sleep disturbance impair combat soldiers' functioning. The alpha-1 adrenoreceptor antagonist prazosin has been demonstrated effective for these symptoms in Vietnam veterans. Thirteen soldiers seeking relief from distressing trauma nightmares impairing military function in northern Iraq in 2006 received prazosin alone or in combination with other psychotropics. Mean prazosin dose was 4.1 (SD = 2.2) mg before bed. Six soldiers improved markedly and 3 moderately on the Clinical Global Impression of Change Ratings of distressing dreams decreased from an average of 7.0 (SD = 0.7) to 2.9 (SD = 3.0, p < .001) and those of disturbed sleep from 6.7 (SD = 0.9) to 3.7 (SD = 2.4, p < .001). Prazosin appears effective and well tolerated in the desert warfare environment.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Initial posttraumatic stress disorder (PTSD) care is often delayed and many with PTSD go untreated. Acupuncture appears to be a safe, potentially nonstigmatizing treatment that reduces symptoms of anxiety, depression, and chronic pain, but little is known about its effect on PTSD. Methods: Fifty-five service members meeting research diagnostic criteria for PTSD were randomized to usual PTSD care (UPC) plus eight 60-minute sessions of acupuncture conducted twice weekly or to UPC alone. Outcomes were assessed at baseline and 4, 8, and 12 weeks postrandomization. The primary study outcomes were difference in PTSD symptom improvement on the PTSD Checklist (PCL) and the Clinician administered PTSD Scale (CAPS) from baseline to 12-week follow-up between the 2 treatment groups. Secondary outcomes were depression, pain severity, and mental and physical health functioning. Mixed model regression and t test analyses were applied to the data. Results: Mean improvement in PTSD severity was significantly greater among those receiving acupuncture than in those receiving UPC (PCLD = 19.8 ± 13.3 vs. 9.7 ± 12.9, P < 0.001; CAPSD = 35.0± 20.26 vs. 10.9 ± 20.8, P < 0.0001). Acupuncture was also associated with significantly greater improvements in depression, pain, and physical and mental health functioning. Pre-post effect-sizes for these outcomes were large and robust. Conclusions: Acupuncture was effective for reducing PTSD symptoms. Limitations included small sample size and inability to parse specific treatment mechanisms. Larger multisite trials with longer follow-up, comparisons to standard PTSD treatments, and assessments of treatment acceptability are needed. Acupuncture is a novel therapeutic option that may help to improve population reach of PTSD treatment.
    Medical Care 12/2014; 52(12 (Supplement 5)):S57. · 3.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CONTEXTO: Prazosina, um antagonista de receptores alfa-1 adrenérgicos, é utilizada no tratamento de pesadelos e insônia relacionados com TEPT. Apesar das evidências sugerindo sua eficácia também no tratamento de sintomas gerais de TEPT, sua curta meia-vida (2-3 horas) pode limitar seus efeitos terapêuticos. OBJETIVO: Descrever quatro casos de pacientes com TEPT resistentes aos inibidores de recaptação de serotonina ou de serotonina e adrenalina (terapia convencional) tratados com uma apresentação de prazosina de liberação lenta. MÉTODOS: Quatro pacientes com TEPT grave, resistentes à terapia convencional, tiveram a prazosina de liberação lenta (meia-vida de 10,8 horas) adicionada as suas prescrições por pelo menos três meses. Os sintomas de TEPT foram avaliados pela PCL-C e pelos itens referentes a pesadelos e insônia da CAPS, na linha de base e no final do período de observação de cada paciente. RESULTADOS: Dois pacientes mostraram melhora dos sintomas gerais de TEPT (redução de 35,7% e 11,9% nos escores da PCL-C), e três mostraram melhora de pesadelos e insônia (nos escores da CAPS). O único paciente que recebeu doses da prazosina pela manhã e ao deitar-se foi o que mostrou a maior melhora dos sintomas gerais de TEPT. CONCLUSÃO: Possivelmente, a sustentação do bloqueio da atividade noradrenérgica no sistema nervoso central promovida pela prazosina de liberação lenta durante o dia se faz necessária para a melhora de sintomas residuais de TEPT em pacientes em tratamento convencional com antidepressivos.
    Revista de Psiquiatria Clínica 12/2011; 39(5):176-179. · 0.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Improved access to effective primary care-based treatments for PTSD may permit early intervention among previously underserved service members, thereby improving long-term outcomes. This randomized controlled trial examined the efficacy of DESTRESS-PC, a brief, self-directed, cognitive-behavioral, web-based intervention specifically tailored to the treatment of war-related Posttraumatic Stress Disorder (PTSD), compared to Optimized Usual Primary Care PTSD Treatment (OUC). Participants were 80 veterans of recent military conflicts with PTSD seeking primary care treatment at one of three Veterans Affairs (VA) and four Army clinics. DESTRESS-PC consisted of logins to a secure website three times per week for six weeks and monitoring by a study nurse. All participants received nurse care management in the form of phone check-ins every two weeks and feedback to their primary care providers. Blinded raters assessed outcomes 6, 12, and 18 weeks post-randomization. Study hypotheses were partially supported. DESTRESS-PC was associated with a significantly greater decrease in PTSD (PCLprimary outcome) and depression (PHQ-8) symptoms compared to OUC at the 12-week assessment (PCL = 12.616.6 versus 5.712.5, p<0.05; PHQ-8 = 3.6 4.9 versus 1.54.4, p<.05). VA participants (but not DoD participants) evidenced a similar pattern of results; yet, between-group effect sizes were larger, ranging from .30 to .59. Notably, there was a dose effect: the number of logins correlated significantly with PTSD outcomes. None of the other secondary outcomes (anxiety, somatic symptoms, and functional status) were significant. DESTRESS-PC offers promise as a means of delivering effective, early PTSD treatment in primary care to reduce chronicity, particularly for Veterans.
    141st APHA Annual Meeting and Exposition 2013; 11/2013


Available from